Investment Banking
Co-Lead Manager on Centessa Pharmaceuticals' $287.5MM CMPO
November 19, 2025
Oppenheimer & Co. Inc. acted as Co-Lead Manager on Centessa Pharmaceuticals’ $287.5MM Confidentially Marketed Public Offering
Centessa Pharmaceuticals, a clinical-stage pharmaceutical company, announced an underwritten public offering of 13,372,093 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $21.50 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $287.5MM, before deducting underwriting discounts and commissions and offering expenses.
Healthcare Life Sciences Investment Banking
Name:
Michael A. Margolis, R.Ph.
Title:Senior Managing Director, Head of Healthcare Life Sciences Investment Banking
Healthcare Equity Capital Markets
Name:
Andy Linderman
Title:Managing Director, Healthcare Capital Markets Investment Banking
Name:
James Yoo
Title:Managing Director, Healthcare Capital Markets Investment Banking
DISCLOSURES
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
Oppenheimer & Co. Inc. Transacts Business on all Principal US Exchanges and is a Member of SIPC. 8613113.1